



**COLORADO**

Department of Health Care  
Policy & Financing

**AGENDA**  
**Pharmaceuticals & Therapeutics Committee**  
**Department of Health Care Policy & Financing**

Zoom Webinar:

[https://magellanhealth.zoom.us/webinar/register/WN\\_KSQv5nzhRtGgCEf0uBAbnA](https://magellanhealth.zoom.us/webinar/register/WN_KSQv5nzhRtGgCEf0uBAbnA)

Tuesday, July 11, 2023, 1:00-5:00 P.M.

**1. Committee Member Introductions**

**2. Unfinished Business and General Orders**

Approval of minutes from April 4, 2023 P&T meeting  
Updates from April 4, 2023 P&T Meeting

**3. New Business**

Updates from the Prior Authorization Call Center

**4. Drug Classes Up for Review**

Review of Bone Resorption Suppression and Related Agents

Review of Contraceptives - Topical

Review of Diabetes Management Classes - Insulins - Long-Acting, Concentrated

Review of Diabetes Management Classes - Non-Insulin

GLP-1 Analogues, SGLT-2is

Review of Growth Hormones

Review of Benign Prostatic Hyperplasia (BPH) Agents

Review of Overactive Bladder Agents

Mass review drug classes:

- Androgenic Agents - Topical, Injectable, Oral
- Diabetes Management Classes - Insulins - Rapid, Short, Intermediate, Mixtures
- Diabetes Management Classes - Non-Insulins
  - Amylin, Biguanides, DPP-4is, Meglitinides, TZDs, Combinations
- Estrogen Agents - Oral/Transdermal, Injectable
- Glucagon, Self-Administered
- Phosphate Binders
- Prenatal Vitamins/Minerals
- Antihyperuricemics

Improving health care equity, access, and outcomes for the people we serve while  
saving Coloradans money on health care and driving value for Colorado.

[www.colorado.gov/hcpf](http://www.colorado.gov/hcpf)



Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass Review drug classes will only include:

- Overview for each Drug Class, including market share overview

Presentations:

- Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical testimony that will be presented for P&T Committee dissemination.
- Advance notice requests to present and/or written public comments can be submitted to Jessica Czechowski, Pharmacist Account Executive, [jlczechowski@magellanhealth.com](mailto:jlczechowski@magellanhealth.com) and carbon copy: Mohamed Duklef, Clinical Pharmacist, [mohamed.duklef@state.co.us](mailto:mohamed.duklef@state.co.us). Once approved, public comments will be distributed to P&T Committee Members.
- Requests and public comment summaries are due by **June 29<sup>th</sup>, 2023 by 5pm MST**.

## 5. Adjourn

Upcoming Meeting Date: October 3, 2023.

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the [504/ADA Coordinator](#) or [hcpf504ada@state.co.us](mailto:hcpf504ada@state.co.us) at least one week prior to the meeting to make arrangements.

